Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase
Standard
Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase. / Warren, Christopher M; van den Brink, Ruud L; Nieuwenhuis, Sander; Bosch, Jos A.
In: PSYCHONEUROENDOCRINO, Vol. 78, 04.2017, p. 233-236.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase
AU - Warren, Christopher M
AU - van den Brink, Ruud L
AU - Nieuwenhuis, Sander
AU - Bosch, Jos A
N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.
PY - 2017/4
Y1 - 2017/4
N2 - It has been suggested that central norepinephrine (NE) activity may be inferred from increases in salivary alpha-amylase (SAA), but data in favor of this proposition are limited. We administered 40mg of atomoxetine, a selective NE transporter blocker that increases central NE levels, to 24 healthy adult participants in a double-blind, placebo-controlled cross-over design. Atomoxetine administration significantly increased SAA secretion and concentrations at 75-180min after treatment (more than doubling baseline levels). Consistent with evidence that elevation in central NE is a co-determinant of hypothalamic-pituitary-adrenal axis activity, salivary cortisol also approximately doubled at the same time points. Moreover, changes in salivary cortisol positively correlated with SAA (0.44
AB - It has been suggested that central norepinephrine (NE) activity may be inferred from increases in salivary alpha-amylase (SAA), but data in favor of this proposition are limited. We administered 40mg of atomoxetine, a selective NE transporter blocker that increases central NE levels, to 24 healthy adult participants in a double-blind, placebo-controlled cross-over design. Atomoxetine administration significantly increased SAA secretion and concentrations at 75-180min after treatment (more than doubling baseline levels). Consistent with evidence that elevation in central NE is a co-determinant of hypothalamic-pituitary-adrenal axis activity, salivary cortisol also approximately doubled at the same time points. Moreover, changes in salivary cortisol positively correlated with SAA (0.44
KW - Adrenergic Uptake Inhibitors
KW - Adult
KW - Atomoxetine Hydrochloride
KW - Cross-Over Studies
KW - Double-Blind Method
KW - Female
KW - Humans
KW - Hydrocortisone
KW - Hypothalamo-Hypophyseal System
KW - Male
KW - Pituitary-Adrenal System
KW - Saliva
KW - Salivary alpha-Amylases
KW - Young Adult
KW - Journal Article
KW - Randomized Controlled Trial
U2 - 10.1016/j.psyneuen.2017.01.029
DO - 10.1016/j.psyneuen.2017.01.029
M3 - SCORING: Journal article
C2 - 28232237
VL - 78
SP - 233
EP - 236
JO - PSYCHONEUROENDOCRINO
JF - PSYCHONEUROENDOCRINO
SN - 0306-4530
ER -